Cardiovascular Risk in Patients With Takayasu Arteritis: A Nationwide Population-Based Cohort Study (NCT07686991) | Clinical Trial Compass
CompletedNot Applicable
Cardiovascular Risk in Patients With Takayasu Arteritis: A Nationwide Population-Based Cohort Study
France8,275 participantsStarted 2010-01-01
Plain-language summary
This nationwide observational cohort study compares the risk of major adverse cardiovascular events (MACE) and territory-specific arterial complications between patients with incident Takayasu arteritis and matched general-population controls, and identifies determinants of MACE within the Takayasu arteritis population, including cumulative glucocorticoid exposure, using the French National Health Data System (SNDS).
Who can participate
Age range
15 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Age 15 to 60 years Cases: incident hospital diagnosis of Takayasu arteritis (ICD-10 M31.4) recorded as principal, related, or associated diagnosis between 2010 and 2024 Cases matched 4:1 to general-population controls (exact on sex and region; calipers on year of birth and propensity-score logit) Controls: alive and active in the database at the index date (≥1 reimbursed contact in the prior 365 days), residing in the same region, with no recorded Takayasu arteritis diagnosis
Exclusion Criteria:
Cases who could not be matched to at least four eligible general-population controls Age outside the 15 to 60 years range at the index date
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Major Adverse Cardiovascular Events (MACE)
Timeframe: Up to 15 years (January 2010 to December 2024)
Trial details
NCT IDNCT07686991
SponsorGroupe français d'étude des Maladies Inflammatoires de loeil